416 related articles for article (PubMed ID: 16325893)
1. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
; Markman M; Blessing J; Rubin SC; Connor J; Hanjani P; Waggoner S
Gynecol Oncol; 2006 Jun; 101(3):436-40. PubMed ID: 16325893
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
[TBL] [Abstract][Full Text] [Related]
4. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
Linch M; Stavridi F; Hook J; Barbachano Y; Gore M; Kaye SB
Gynecol Oncol; 2008 Apr; 109(1):27-32. PubMed ID: 18262259
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma].
Fujii K; Takano M; Okamoto S; Sasaki N; Kita T; Kikuchi Y
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2141-4. PubMed ID: 15628759
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
Rose PG; Smrekar M; Fusco N
Gynecol Oncol; 2005 Feb; 96(2):296-300. PubMed ID: 15661211
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
13. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
14. Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: an extended follow-up.
Skinner EN; Boruta DM; Gehrig PA; Boggess JF; Fowler WC; Van Le L
Gynecol Oncol; 2005 Jul; 98(1):59-62. PubMed ID: 15913741
[TBL] [Abstract][Full Text] [Related]
15. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Sabbatini P; Aghajanian C; Dizon D; Anderson S; Dupont J; Brown JV; Peters WA; Jacobs A; Mehdi A; Rivkin S; Eisenfeld AJ; Spriggs D
J Clin Oncol; 2004 Nov; 22(22):4523-31. PubMed ID: 15542803
[TBL] [Abstract][Full Text] [Related]
18. Weekly paclitaxel in the management of ovarian cancer.
Markman M
Semin Oncol; 2000 Jun; 27(3 Suppl 7):37-40. PubMed ID: 10952125
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
[TBL] [Abstract][Full Text] [Related]
20. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
